Page 43 - MemoriaBBN-Eng

www.ciber-bbn.es

• “CIBER BBN – OFTARED Clinical Forum in Ophthalmology” (Instituto de Salud

Carlos III, Madrid, 06/27/2013), organized together with OFTARED (Thematic
Network of Collaborative Research in Ophthalmology). Around 65 people in-

cluding clinics, companies, investigators and scientific managers participated.

• “CIBER BBN – RIC Clinical Forum in Cardiology” (Vall d’Hebron Hospital, Bar-

celona, 12/16/2013) in collaboration with RIC (Thematic Network of Cardio-
vascular Research). Around 115 people including clinics, investigators and

scientific managers attended.

Outlook on technology and Technology Surveillance

A non-disclosure agreements was signed in February with the company B-ABLE to
í
study the viability of creating a spin-off based on the patent co-owned by CIBER-
BBN “Release of substances into senescent cells (P201231370)”, for which confi-

dential information was provided B-ABLE, who informed that it was interested in

the technology up to the creation of a spin off.

Two non-disclosure agreements were signed with companies (for the sake of sim-
plicity, the majority co-owner signs on behalf of CIBER):

• NDA signed with Aseptika (UK) for its interest in the patent Haptenos y conju-

gados derivados de piocianina, anticuerpos de los mismos, y método inmuno-
qumico para la detección de infecciones provocadas por pseudomonas aeru-

ginosa, (Haptens and conjugates derived from pyocyanin, antibodies thereof

and immunochemical method for detecting infections caused by pseudomonas
aeruginosa) P201330312.

• NDA signed with Ophtimalia (France) for its interest in the intramural project,

Glauco.

Non-confidential information was sent to 34 companies.

A process was conducted in 2013 to give priority and value to 20 CIBER-BBN te-

chnologies (patents and intramural projects) considering their transfer potential.
This process consisted of three phases: first, analysing the 20 technologies and

selecting five with the highest potential for a more in-depth evaluation, then selec-

ting the technology (the patent “Functionalized liposomes useful for bioactive com-
pound delivery” with the highest transfer potential. A development plan has been

prepared for this patent to make sure it meets significant high-value milestones
allowing it to be licensed to an industrial partner.
13
20
Aspects such as the non-covered need for the product/technology, market poten- T
OR
tial, current and future competition, technological novelty, intellectual property, P
RE
regulatory environment, project viability and capacity to carry it out.
L
A
NU
N
A
Technological Offer and Conferences
N /
B
-B
Informative material in the form of brochures, posters, flyers for patents and pro- R
jects, etc., containing the latest information concerning our technological offer and BE
CI
all the units of services grouped as a single infrastructure has been designed.

43